CN103210085B - 用于治疗或诊断骨障碍和/或心血管障碍的组合物 - Google Patents

用于治疗或诊断骨障碍和/或心血管障碍的组合物 Download PDF

Info

Publication number
CN103210085B
CN103210085B CN201180034123.1A CN201180034123A CN103210085B CN 103210085 B CN103210085 B CN 103210085B CN 201180034123 A CN201180034123 A CN 201180034123A CN 103210085 B CN103210085 B CN 103210085B
Authority
CN
China
Prior art keywords
mir
polynucleotide
nucleic acid
fzd3
context
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180034123.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103210085A (zh
Inventor
J·格里拉瑞
E·施拉姆尔
K·弗奇埃格
R·格里拉瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet fuer Bodenkultur Wien BOKU
Original Assignee
Universitaet fuer Bodenkultur Wien BOKU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet fuer Bodenkultur Wien BOKU filed Critical Universitaet fuer Bodenkultur Wien BOKU
Publication of CN103210085A publication Critical patent/CN103210085A/zh
Application granted granted Critical
Publication of CN103210085B publication Critical patent/CN103210085B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
CN201180034123.1A 2010-05-21 2011-05-23 用于治疗或诊断骨障碍和/或心血管障碍的组合物 Expired - Fee Related CN103210085B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10163604 2010-05-21
EP10163604.1 2010-05-21
PCT/EP2011/058379 WO2011144761A1 (en) 2010-05-21 2011-05-23 Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders

Publications (2)

Publication Number Publication Date
CN103210085A CN103210085A (zh) 2013-07-17
CN103210085B true CN103210085B (zh) 2018-09-25

Family

ID=44537805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180034123.1A Expired - Fee Related CN103210085B (zh) 2010-05-21 2011-05-23 用于治疗或诊断骨障碍和/或心血管障碍的组合物

Country Status (7)

Country Link
US (3) US20130108687A1 (enExample)
EP (1) EP2571988B1 (enExample)
JP (1) JP5894581B2 (enExample)
CN (1) CN103210085B (enExample)
BR (1) BR112012029656A2 (enExample)
CA (1) CA2800018C (enExample)
WO (1) WO2011144761A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316342A (zh) * 2013-02-28 2013-09-25 中国人民解放军沈阳军区总医院 MiR-31抑制剂用于抑制血管损伤后再狭窄的用途
GB201309882D0 (en) * 2013-06-03 2013-07-17 Isis Innovation Prevention and treatment of atrial fibrillation
WO2014197747A1 (en) * 2013-06-05 2014-12-11 The Trustees Of Columbia University In The City Of New York Exosomes for orofacial diagnostics and therapeutics
CN103627705B (zh) * 2013-10-28 2016-02-24 南京医科大学 与膀胱癌相关的piRNA生物标志物及其应用
WO2015189345A2 (en) * 2014-06-13 2015-12-17 Universität Für Bodenkultur Wien Compositions and methods for the diagnosis and treatment of bone fractures and disorders
WO2016094406A1 (en) * 2014-12-08 2016-06-16 Thomas Jefferson University Treatment and prevention of thrombosis using an anti-mir
JP6694240B2 (ja) * 2015-01-30 2020-05-13 ロート製薬株式会社 細胞の品質を評価する方法、及び細胞の品質判定キット
CN107176976B (zh) * 2016-03-11 2020-02-14 上海交通大学医学院 微小rna31前体编码多肽在制备免疫调节药物中的应用
CN107151695B (zh) * 2016-12-08 2021-11-09 青岛大学 用于检测急性心肌缺血疾病的piRNA组合及其检测方法和应用
CN110129429A (zh) * 2019-05-22 2019-08-16 昌乐县人民医院 核酸分子在制备诊断骨科疾病的产品中的应用
CN110184270A (zh) * 2019-05-31 2019-08-30 固安博健生物技术有限公司 非编码rna作为男性骨质疏松症的诊断标志物
CN110055256A (zh) * 2019-05-31 2019-07-26 固安博健生物技术有限公司 Loc105376287作为诊断男性骨质疏松症的分子标志物的用途
CN110951869B (zh) * 2020-01-02 2021-06-18 北京市创伤骨科研究所 骨质疏松诊治用生物标志物
CN111118139B (zh) * 2020-01-13 2021-06-18 北京市创伤骨科研究所 一种骨质疏松的分子靶标及其应用
CN111599476B (zh) * 2020-05-15 2023-08-11 中南大学湘雅医院 一种高血压的预测模型及其建立方法以及用于预测高血压的生物标记物
CN112746101B (zh) * 2020-12-25 2023-02-28 深圳市人民医院 一种骨质疏松诊断标志物及促进骨质疏松骨再生的核酸药物
CN114426950B (zh) * 2022-01-25 2023-08-04 北京大学口腔医学院 一种高成骨成血管的血清外泌体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112754A2 (en) * 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
EP0943684A3 (en) * 1998-03-10 2002-01-23 Smithkline Beecham Plc Frizzled-like polypeptides and polynucleotides
US7655785B1 (en) * 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
PT1913952E (pt) * 2002-12-05 2011-04-14 Univ Arkansas Determinantes moleculares da doença óssea do mieloma e respectivas utilizações
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
AR043507A1 (es) 2003-03-14 2005-08-03 Lundbeck & Co As H Derivados de anilina sustituidos y composiciones farmaceuticas
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
CA2556435C (en) * 2004-02-13 2014-08-12 The Rockefeller University Anti-microrna oligonucleotide molecules
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
WO2008013963A2 (en) 2006-07-28 2008-01-31 University Of Connecticut Fatty acid amide hydrolase inhibitors
US7993831B2 (en) * 2007-09-14 2011-08-09 Asuragen, Inc. Methods of normalization in microRNA detection assays
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
US20130210883A1 (en) 2010-05-21 2013-08-15 Johannes Grillari Lipase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112754A2 (en) * 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A Pleiotropically Acting MicroRNA,miR-31, Inhibits Breast Cancer Metastasis;Scott等;《CELL》;20090612;第137卷(第6期);第1035页左栏第4-5段 *
Characterization of function and regulation of miR-24-1 and miR-31;Sun等;《Biochemical and Biophysical Research Communications》;20090313;第380卷(第3期);第661页右栏第4段 *
The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-a and MMP13;Jones等;《Osteoarthritis and Cartilage》;20090401;第17卷(第4期);第466页表1 *

Also Published As

Publication number Publication date
EP2571988B1 (en) 2019-11-20
US9150855B2 (en) 2015-10-06
JP5894581B2 (ja) 2016-03-30
BR112012029656A2 (pt) 2016-12-13
US20140162265A1 (en) 2014-06-12
US20150119450A1 (en) 2015-04-30
JP2013534908A (ja) 2013-09-09
EP2571988A1 (en) 2013-03-27
US9212362B2 (en) 2015-12-15
CA2800018C (en) 2021-09-28
CA2800018A1 (en) 2011-11-24
WO2011144761A1 (en) 2011-11-24
CN103210085A (zh) 2013-07-17
US20130108687A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
CN103210085B (zh) 用于治疗或诊断骨障碍和/或心血管障碍的组合物
US9320756B2 (en) UCP1 (thermogenin)—inducing agents for use in the treatment of a disorder of the energy homeostasis
US9255268B2 (en) Methods for diagnosing and treating learning or mental disorders
JP5898843B2 (ja) 血管新生、血管形成、若しくは血管修復を促進するか、又は腫瘍血管新生を阻害する方法
US9862948B2 (en) Microrna inhibition for the treatment of inflammation and myeloproliferative disorders
CN104011208B (zh) 作为治疗靶的miRNA-212/132家族
JPWO2008029790A1 (ja) 新規核酸
JPWO2008084319A1 (ja) 新規核酸
US9322015B2 (en) Methods of using microRNA-26a to promote angiogenesis
EP3302522B1 (en) Means and methods for treating facioscapulohumeral muscular dystrophy (fshd).
US20150190532A1 (en) Smooth muscle specific inhibition for anti-restenotic therapy
US20230287427A1 (en) Inhibition of lncExACT1 to Treat Heart Disease
WO2024229137A1 (en) Apoe-activating noncoding rna (erna) and uses thereof
JP4851940B2 (ja) がんまたは糖尿病治療のための医薬組成物
JPWO2005010185A1 (ja) Ｋｌｆ５遺伝子の発現を抑制するｒｎａ
US20180008641A1 (en) Use of MicroRNA 375 in Augmenting Stem Cell Based and Endogenous Ischemic Tissue Repair

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180925

CF01 Termination of patent right due to non-payment of annual fee